Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $1.9 million.

  • Anika Therapeutics' Capital Expenditures rose 5518.09% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 945.93%. This contributed to the annual value of $7.7 million for FY2024, which is 4250.97% up from last year.
  • Latest data reveals that Anika Therapeutics reported Capital Expenditures of $1.9 million as of Q3 2025, which was up 5518.09% from $1.5 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Capital Expenditures high stood at $3.4 million for Q2 2024, and its period low was $570000.0 during Q1 2021.
  • Its 5-year average for Capital Expenditures is $1.7 million, with a median of $1.5 million in 2025.
  • Per our database at Business Quant, Anika Therapeutics' Capital Expenditures surged by 106864.86% in 2021 and then tumbled by 5689.1% in 2025.
  • Over the past 5 years, Anika Therapeutics' Capital Expenditures (Quarter) stood at $1.1 million in 2021, then surged by 124.4% to $2.5 million in 2022, then decreased by 27.24% to $1.8 million in 2023, then fell by 28.97% to $1.3 million in 2024, then surged by 44.38% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $1.5 million for Q2 2025, and $2.8 million during Q1 2025.